Literature DB >> 10217357

Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins.

H J Pownall1, D Brauchi, C Kilinç, K Osmundsen, Q Pao, C Payton-Ross, A M Gotto, C M Ballantyne.   

Abstract

Serum triglyceride (TG) and high-density lipoprotein cholesterol (HDL-C) concentrations are inversely correlated and mechanistically linked by means of lipid transfer activities. Phospholipid transfer activity (PLTA) moves phospholipids among serum lipoproteins; cholesteryl ester transfer activity (CETA), which exchanges cholesteryl esters (CE) and TG among lipoproteins, is stimulated by nonesterified fatty acids (NEFA). The aims of this study were (a) to develop a quantitative model that correlates the neutral lipid (NL = CE + TG) compositions of HDL and LDL with serum TG concentration; (b) identify the serum lipid determinants of CETA and PLTA, and; (c) identify the effects of serum TG reductions on the neutral lipid compositions of HDL and LDL, serum NEFA concentrations, and on PLTA and CETA. These aims were addressed in 40 hypertriglyceridemic subjects before and after treatment with an 85% concentrate of omega-3 fatty acids (Omacor) and in 16 untreated normolipidemic subjects. In vivo, the NL compositions of LDL and HDL were described by a mathematical model having the form of adsorption isotherms: HDL - (TG/NL) = (0.90 +/- 0.07) serum TG/(7.0 +/- 1.2 mmol/l + serum TG) and LDL - (TG/NL) = (0.65 +/- 0.08) serum TG/(4.9 +/- 1.5 mmol/l + serum TG). Reduction of serum TG was associated with reductions in HDL - (TG/NL), serum NEFA concentration, and serum CETA but not PLTA. These data suggest that both hypertriglyceridemia and the attendant elevated serum CETA but not PLTA are determinants of HDL and LDL composition and structure and that serum TG concentrations are good predictors of the NL compositions of HDL and LDL.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10217357     DOI: 10.1016/s0021-9150(98)00301-3

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  46 in total

Review 1.  Dietary supplements and cardiovascular disease.

Authors:  R M DeBusk
Journal:  Curr Atheroscler Rep       Date:  2000-11       Impact factor: 5.113

2.  Serum opacity factor enhances HDL-mediated cholesterol efflux, esterification and anti inflammatory effects.

Authors:  Urbain Tchoua; Corina Rosales; Daming Tang; Baiba K Gillard; Ashley Vaughan; Hu Yu Lin; Harry S Courtney; Henry J Pownall
Journal:  Lipids       Date:  2010-10-24       Impact factor: 1.880

3.  A Comparative Overview of Prescription Omega-3 Fatty Acid Products.

Authors:  Matthew K Ito
Journal:  P T       Date:  2015-12

Review 4.  Long-chain n-3 polyunsaturated fatty acids: new insights into mechanisms relating to inflammation and coronary heart disease.

Authors:  Baukje de Roos; Yiannis Mavrommatis; Ingeborg A Brouwer
Journal:  Br J Pharmacol       Date:  2009-05-05       Impact factor: 8.739

Review 5.  The metabolic syndrome.

Authors:  Marc-Andre Cornier; Dana Dabelea; Teri L Hernandez; Rachel C Lindstrom; Amy J Steig; Nicole R Stob; Rachael E Van Pelt; Hong Wang; Robert H Eckel
Journal:  Endocr Rev       Date:  2008-10-29       Impact factor: 19.871

Review 6.  Metabolic syndrome, diabetes, and cardiovascular risk in HIV.

Authors:  Linda M Nix; Phyllis C Tien
Journal:  Curr HIV/AIDS Rep       Date:  2014-09       Impact factor: 5.071

7.  Signaling pathways modulated by fish oil in salt-sensitive hypertension.

Authors:  Montserrat M Diaz Encarnacion; Gina M Warner; Catherine E Gray; Jingfei Cheng; Hesham K H Keryakos; Karl A Nath; Joseph P Grande
Journal:  Am J Physiol Renal Physiol       Date:  2008-04-02

8.  Altered relationship of plasma triglycerides to HDL cholesterol in patients with HIV/HAART-associated dyslipidemia: further evidence for a unique form of metabolic syndrome in HIV patients.

Authors:  Catherine N Vu; Raul Ruiz-Esponda; Eric Yang; Evelyn Chang; Baiba Gillard; Henry J Pownall; Ron C Hoogeveen; Ivonne Coraza; Ashok Balasubramanyam
Journal:  Metabolism       Date:  2013-03-19       Impact factor: 8.694

Review 9.  Review of Cardiometabolic Effects of Prescription Omega-3 Fatty Acids.

Authors:  Megan F Burke; Frances M Burke; Daniel E Soffer
Journal:  Curr Atheroscler Rep       Date:  2017-11-07       Impact factor: 5.113

Review 10.  Omega-3 ethylester concentrate: a review of its use in secondary prevention post-myocardial infarction and the treatment of hypertriglyceridaemia.

Authors:  Sheridan M Hoy; Gillian M Keating
Journal:  Drugs       Date:  2009-05-29       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.